You saw the temple recession in a work-trip photo, you did the Reddit deep-dives, and now you have hit the threads that worry you the most: the ones about sexual side effects and mood changes that some men report do not go away. That worry deserves a real answer, not hype and not a hand-wave.
This article is educational and is not medical advice. It will not tell you whether to start any medication. It will walk through what the reported side-effect profile for finasteride actually looks like in the literature, what "post-finasteride syndrome" (PSSD, sometimes discussed as PFS) refers to and where the evidence stands, and how an independent provider typically frames baseline questions and monitoring before anyone touches a prescription.
What finasteride does, mechanically
Finasteride is a 5-alpha-reductase inhibitor. It blocks the enzyme that converts testosterone into dihydrotestosterone (DHT), the androgen most associated with the miniaturization of scalp hair follicles in male pattern hair loss [1]. The oral formulation used for hair loss reduces circulating and scalp DHT substantially, which is the whole point: less DHT at the follicle is the mechanism behind slowing androgenetic hair loss [1][2].
That same mechanism is why side-effect questions exist. DHT is active in tissues beyond the scalp, including those involved in sexual function. So the conversation is not about whether the drug "does something" systemically. It does. The conversation is about how often reported effects occur, how they present, and how they are monitored.
What the reported side-effect profile actually shows
Here is the honest state of the data, because you have clearly already read the scary version.
In the original controlled trials supporting the 1 mg hair-loss indication, sexual adverse events (things like decreased libido, erectile difficulty, and ejaculation changes) were reported at low single-digit percentages, and were modestly higher than placebo [2]. The FDA-approved labeling reflects this and lists these effects, along with a note that some men have reported persistence of sexual dysfunction after stopping the drug, and reports of depressed mood and, separately, reports concerning suicidal ideation [3]. That labeling language matters: it is why a careful provider raises these topics directly rather than pretending they do not exist.
{{FIGURE:1}}
The important nuance is around persistence and causality. "Post-finasteride syndrome" describes a cluster of sexual, physical, and neuropsychiatric symptoms that some men report continuing after they stop the medication. It is a genuinely reported phenomenon and is taken seriously enough to appear in the label and in pharmacovigilance literature [3][4]. It is also not fully characterized: the medical literature describes it as poorly understood, without an agreed diagnostic definition, and with real difficulty separating drug effect from other contributors in the available reports [4]. In plain English: the reports are real and worth respecting, the mechanism and the true rate are not settled, and no one can honestly quote you a clean probability number for it.
That is exactly why a serious provider does not respond to your worry with "it's rare, don't worry about it." That is a reassurance claim, and it is not one anyone should make to you.
How a provider frames baseline questions before you start
The point of a proper evaluation is to establish where you are *before* any medication, so that a change actually means something later. You cannot flag a shift from baseline if no one recorded the baseline.
An independent provider review typically covers:
- Sexual function baseline. Current libido, erectile function, and ejaculatory function, in your own words. Some clinicians use structured questionnaires so there is a repeatable reference point rather than a vague memory [1].
- Mood and mental health baseline. History of depression or anxiety, current mood, and any prior reactions to medications. The labeling reference to mood changes is the reason this is a standard part of the conversation, not an afterthought [3].
- Family and personal medical history. Your early hair-loss pattern and family history are relevant to the hair discussion; other conditions and medications are relevant to safety.
- Your goals and risk tolerance. Wanting to keep the hair you have is a different conversation than any other goal, and your own comfort with the reported risks is part of the decision.
{{FIGURE:2}}
Providers may also discuss labs. Finasteride is known to lower prostate-specific antigen (PSA) readings, roughly cutting them, which matters for how future PSA results are interpreted at any age where PSA screening applies [3]. Knowing you are on the medication changes how a clinician reads that number later, so it belongs in your record.
Source: [1] Kelly Y, et al. Androgenetic Alopecia: An Update of Treatment Options (review of 5-alpha-reductase inhibition and finasteride), [3] U.S. FDA. Finasteride 1 mg Prescribing Information (adverse reactions, PSA effects, post-marketing reports)
When to flag a change
The practical framing most providers give is straightforward: you are the monitor between visits. Because a baseline was established, you have something to compare against. Things generally worth reporting promptly include:
- A noticeable change in libido, erectile function, or ejaculation.
- Any change in mood, motivation, or mental state, and *urgently*, any thoughts of self-harm [3].
- Physical symptoms such as breast tenderness or lumps, which the label flags for evaluation [3].
- Anything that simply feels different and concerning to you.
The decision about whether to continue, pause, or stop is a clinical one made with an independent provider, not something to reverse-engineer from a forum. "Should I quit if I notice X" is a question for the person who evaluated you, because the answer depends on your specific picture.
Why sourcing is part of safety
You already know the gray-market problem: an overseas site can send you a bottle with no verified contents, no dosing oversight, and no one to call when something feels off. The side-effect conversation above only works if there is an actual licensed provider on the other end who recorded your baseline and can respond to a change. A checkbox quiz with no real review does not give you that.
A note on formulations: some hair-loss offerings are compounded rather than standard manufactured tablets. If a compounded product is ever involved, this applies: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Where Velri fits
Velri is a technology and coordination company. It does not provide medical care and employs no physicians. What Velri coordinates is the infrastructure around a real evaluation: organizing any appropriate baseline labs, connecting you with an independent, physician-led Provider Group for a genuine visit through the Velri clinical review process, and, only if an independent licensed provider decides it is appropriate, coordinating fulfillment through an independent, licensed pharmacy.
A prescription is never guaranteed. Whether any medication is appropriate for you is decided solely by the independent provider who evaluates you, including the full side-effect discussion described here. Velri's role is to make that process legitimate and organized instead of leaving you sourcing from an unvetted site. Coverage currently starts in Nevada, with more states rolling out over time.
This article is educational and is not medical advice. Talk with a licensed provider about your specific situation before starting or stopping any medication.
